Last reviewed · How we verify
Prevention of migraine attacks in adults
Approved treatments
- Rimegepant 75mg every other day dosing · Pfizer
Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines. - Rimegepant 75mg daily dosing · Pfizer
Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of migraine attacks in adults patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of migraine attacks in adults treatment landscape brief
- Prevention of migraine attacks in adults treatment updates RSS
Frequently asked questions about Prevention of migraine attacks in adults
What drugs treat Prevention of migraine attacks in adults?
Tracked treatments include Rimegepant 75mg every other day dosing, Rimegepant 75mg daily dosing.
What is the treatment for Prevention of migraine attacks in adults?
Standard treatment for Prevention of migraine attacks in adults includes Rimegepant 75mg every other day dosing, Rimegepant 75mg daily dosing. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of migraine attacks in adults patent cliff · Prevention of migraine attacks in adults CI report
- Treatment: Rimegepant 75mg every other day dosing · Pfizer
- Treatment: Rimegepant 75mg daily dosing · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing